

Molecular Ge **Hereditary Ca**

	Patient Information	an	
NORTH			
YORK GENERAL	*Patient Name:	(Last) (First)	
Making a World of Difference	*D.O.B.:	*Sex: M / F	
Molecular Genetics Laboratory	yyyy / m	nm / dd	
Hereditary Cancer Requisition		· · · · · · · · · · · · · · · · · · ·	
4001 Leslie Street, 3SE-186, Toronto, ON, M2K1E1 Phone: (416) 756-6791 Fax: (416) 756-6197 www.nygh.on.ca/genetics/labs	Address: Postal Code:	(*required)	
specimens may be used anonymously in the lab for test	t development or qualit	royed one year after the test is reported. Some residual ty assurance purposes, unless waived by the patient.	
Sample Information			
☐ Blood in EDTA (lavender) 7 cc ☐ DNA 1 - 5 μg Tissue source:	Spe	cimen Collection Centre:	
 □ Saliva (Oragene collection only) □ Skin biopsy □ Skin tissue culture 2 x T25 flasks 	Coll	ection Date (yyyy/mm/dd):	
Patient Information	•		
Does this individual have cancer and/or other symptoms If yes, specify type: Ethnic background:			
Test Requested			
Is expedited testing required? ☐ No ☐ Yes: R	Reason:		
☐ Hereditary Cancer Testing Common Gene Panels	and Small Gene Par	nels/Single Gene Syndromes (please select on pages 2-3)	
IHC result (please specify if applicable):			
	::	(please attach a report)	
☐ Mutation analysis: Gene: Variant ☐ Familial finding Family member's name: Relationship to this patient:		NYGH Lab #:	
 ☐ Mutation analysis: Gene: Variant ☐ Familial finding Family member's name: Relationship to this patient: ☐ Tumour finding 		NYGH Lab #:	
☐ Mutation analysis: Gene: Variant ☐ Familial finding Family member's name: Relationship to this patient:	Variant:	NYGH Lab #:	
 ☐ Mutation analysis: Gene: Variant ☐ Familial finding Family member's name: Relationship to this patient: ☐ Tumour finding 	Variant:	NYGH Lab #:	
 ☐ Mutation analysis: Gene: Variant ☐ Familial finding Family member's name: Relationship to this patient: ☐ Tumour finding ☐ Variant interpretation update: Gene: 	Variant:(ple	ase attach a copy of the original NYGH report)	
□ Mutation analysis: Gene:	Variant:(ple	NYGH Lab #:	

Report to: (Phys

Name _____ Address _____ City _____ Fax (____) _____ Phone (____)____ Fax (____)___

Signature _____ NYGH LAB USE ONLY

PED #: _____ LAB LABEL:

DATE REC'D:

MG.99.802 v7.0 Page 1



Patient name:		
D.O.B.:		

Here	ditary Cancer Testing Common Gene Panels (sequence	ing and de	eletion/duplication) *deletion/duplication analysis only
	Panels	# Genes	Gene(s)
	Hereditary Breast/Ovarian/Prostate Cancer	19	ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM*, HOXB13 (G84E), MLH1, MSH2, MSH6, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, TP53
	Hereditary GI (Lynch syndrome, Gastric, Pancreas, Polyposis) Cancer	31	APC, ATM, BMPR1A, BRCA1, BRCA2, CDH1, CDKN2A, CHEK2, CTNNA1, EPCAM*, GALNT12, GREM1, MLH1, MLH3, MSH2, MSH3, MSH6, MUTYH, NTHL1, PALB2, PMS2, POLD1, POLE, PTEN, RNF43, RPS20, SDHB, SDHD, SMAD4, STK11, TP53
	Hereditary Breast/Ovarian/Prostate/GI Cancer	36	APC, ATM, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDKN2A, CHEK2, CTNNA1, EPCAM*, GALNT12, GREM1, HOXB13 (G84E), MLH1, MLH3, MSH2, MSH3, MSH6, MUTYH, NTHL1, PALB2, PMS2, POLD1, POLE, PTEN, RAD51C, RAD51D, RNF43, RPS20, SDHB, SDHD, SMAD4, STK11, TP53
	Hereditary Endometrial Cancer	10	BRCA1, BRCA2, EPCAM*, MLH1, MSH2, MSH6, PMS2, POLD1, POLE, PTEN
	Lynch Syndrome	5	EPCAM*, MLH1, MSH2, MSH6, PMS2
	Gastric Cancer LAB CODE: GASTCA	17	APC, ATM, BRCA1, BRCA2, CDH1, CTNNA1, EPCAM*, MLH1, MSH2, MSH6, PALB2, PMS2, SDHB, SDHD, SMAD4, STK11, TP53
	Pancreatic Adenocarcinoma	12	ATM, BRCA1, BRCA2, CDKN2A, EPCAM*, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, TP53
	Polyposis LAB CODE: FP	18	APC, BMPR1A, EPCAM*, GREM1, MLH1, MLH3, MSH2, MSH3, MSH6, MUTYH, NTHL1, PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TP53
	Familial Gastrointestinal Stromal Tumour LAB CODE: GISCA	7	KIT, PDGFRA, SDHA, SDHAF2, SDHB, SDHC, SDHD
	Familial Melanoma LAB CODE: MELAN	7	BAP1, BRCA2, CDK4, CDKN2A, MITF (E318K), POT1, PTEN
	Familial Renal Cancer	15	BAP1, FH, FLCN, MET, MITF (E318K), PTEN, SDHA, SDHAF2, SDHB, SDHC, SDHD, TP53, TSC1, TSC2, VHL
	Hereditary Pheochromocytoma and Paraganglioma	12	FH, MAX, MEN1, NF1, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, TMEM127, VHL
	CNS Tumour	20	APC, EPCAM*, LZTR1, MLH1, MSH2, MSH6, NF1, NF2, PMS2, POLE, POT1, PTCH1, PTEN, SMARCB1, SMARCE1, SUFU, TP53, TSC1, TSC2, VHL
	Soft Tissue Sarcoma	12	APC, ATM, BRCA1, BRCA2, CHEK2, EPCAM*, MLH1, MSH2, MSH6, NF1, PMS2, TP53
	Comprehensive Cancer Panel	76	AIP, APC, ATM, AXIN2, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDC73, CDH1, CDK4, CDKN1B, CDKN2A, CHEK2, CTNNA1, DICER1, EGFR (T790M, V834I, V769M), EGLN1, EPCAM*, EXT1, EXT2, FH, FLCN, GALNT12, GREM1, HOXB13 (G84E), KIT, LZTR1, MAX, MEN1, MET, MITF (E318K), MLH1, MLH3, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PDGFRA, PMS2, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD51C, RAD51D, RB1, RECQL, RET, RNF43, RPS20, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TMEM127, TP53, TSC1, TSC2, VHL

NYGH LAB LABEL:



Patient name:	 	
D.O.B.:		

Smal	Panels and Single Gene Syndrome	s			
	Panels		# Genes	Gene(s)	
	Ashkenazi Jewish Panel	LAB CODE: AJF	7	CHEK2 (c.128	>A), BRCA1 (c.68_69del; c.5266dup), BRCA2 (c.5946del), 3C>T), GREM1 (40 kb upstream dup), G>C), MSH6 (c.3959_3962del; c.3984_3987dup)
	AXIN2-related Attenuated Familial Adenor	natous Polyposis LAB CODE: AXIN2FAP	1	AXIN2	
	BAP1 Tumour Predisposition Syndrome	LAB CODE: BAP1TP	1	BAP1	
	Birt-Hogg-Dube Syndrome	LAB CODE: BHD	1	FLCN	
	Carney Complex	LAB CODE: CARNEY	1	PRKAR1A	
	Familial Adenomatous Polyposis (consider ordering with MUTYH)	LAB CODE: FAP	1 or 2	APC	☐ Add MUTYH
	DICER-associated Syndrome	LAB CODE: DICER	1	DICER1	
	Dysplastic Nevus Syndrome	LAB CODE: DNS	2	CDK4, CDKN2	2A
	Familial Isolated Pituitary Adenoma	LAB CODE: FIPA	1	AIP	
	Hereditary Hyperparathyroidism	LAB CODE: HHPT	2	CDC73, MEN1	
	Hereditary Leiomyomatosis and Renal Cel	l Cancer LAB CODE: LEIOM	1	FH	
	Hereditary Lung Cancer	LAB CODE: HLCA	1	EGFR: T790M; V834I; V769M	
	Li-Fraumeni Syndrome	LAB CODE: LIFRAU	1	TP53	
	MEN1 Syndrome	LAB CODE: MEN1	2	CDKN1B, MEN1	
	Multiple Endocrine Neoplasia Type 2	LAB CODE: MEN2	1	RET	
	Neurofibromatosis Type 1	LAB CODE: NF1	1	NF1	
	Gorlin Syndrome (Nevoid Basal Cell Carci	noma Syndrome) LAB CODE: GORL	2	PTCH1, SUFU	
	Nijmegen Breakage Syndrome	LAB CODE: NBS	1	NBN	
	Peutz-Jeghers Syndrome	LAB CODE: PEUTZ	1	STK11	
	PTEN Hamartoma Tumour Syndrome	LAB CODE: PHTS	1	PTEN	
	Rare Polyposis Genes	LAB CODE: RPOLYP	2	GALNT12, RPS20	
	Retinoblastoma	LAB CODE: RB	1	RB1	
	Rhabdoid Predisposition Syndrome	LAB CODE: RTPS	2	SMARCA4, SMARCB1	
	Schwannomatosis	LAB CODE: SHWAN	3	LZTR1, NF2, SMARCB1	
	Sessile Serrated Polyposis Cancer Syndro	LAB CODE: SSPCS	1	RNF43	
	Small Cell Carcinoma of the Ovary, Hyper	calcemic Type LAB CODE: SCCOHT	1	SMARCA4	
	Tuberous Sclerosis	LAB CODE: TS	2	TSC1, TSC2	
	Von Hippel-Lindau Syndrome	LAB CODE: VHL	1	VHL	

NYGH LAB LABEL:

Sample Requirements

Requisition

Complete this Requisition completely including:

- Patient information: patient's name, date of birth, sex, address and Ontario Health Card number
- Specimen information: specimen type, sample collection centre and date of collection
- Patient/Family information
- Test(s) requested
- Referring physician name, address, phone and fax numbers, and signature
- Genetic counsellor name and contact information
- Any other relevant information

Sample Requirements

- Minimum quantity of sample required is indicated on the requisition.
- Label specimen containers with the individual's first and last names and date of birth.
- Skin biopsy tissue should be collected in sterile saline buffer.

Please note:

- Specimens received for testing in the incorrect anti-coagulant will be rejected.
- Blood specimens from patients who have had a blood transfusion will be accepted three weeks post transfusion.
- Blood specimens from patients who have had an allogenic transplant (bone marrow or stem cell) will <u>not</u> be accepted. In this case, skin biopsy tissue is the preferred sample type.

Shipping Instructions

- Ship specimens at **room temperature** by overnight courier such that the specimen arrives in the Laboratory Monday to Friday between 8:30 and 4:30
- Samples should be shipped as soon as possible after collection
- Specimens held for a few days prior to shipping should be maintained at 4ºC
- When shipping specimens, follow the regulations of the Transportation of Dangerous Goods Act (1992, C.34)